Keyphrases
Pharmacokinetics
56%
Population Pharmacokinetics
24%
Therapeutic Drug Monitoring
22%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
17%
Plasma Concentration
17%
Cyclophosphamide
15%
Human Plasma
15%
Carboplatin
13%
Ritonavir
13%
Thiotepa
13%
Docetaxel
11%
Paclitaxel
11%
Nevirapine
9%
Pharmacokinetic Study
8%
Cancer Patients
8%
Oncology
8%
Population Pharmacokinetic Model
7%
HIV Patients
7%
Clinical Pharmacology
7%
Pharmacodynamics
7%
Monoclonal Antibody
7%
Pazopanib
7%
Active Metabolite
7%
Capecitabine
6%
Efavirenz
6%
High-dose Chemotherapy
6%
Human Immunodeficiency Virus Type 1 (HIV-1)
6%
Confidence Interval
6%
Pharmacokinetic Analysis
6%
Antiviral Drugs
6%
Sunitinib
6%
Gemcitabine
6%
Protease Inhibitors
6%
Drug Interactions
6%
Cmin
6%
Indisulam
5%
Solid Tumors
5%
Population Pharmacokinetic Analysis
5%
Metabolism
5%
NONMEM
5%
Anticancer Drugs
5%
High Dose
5%
Oxaliplatin
5%
Chemotherapy
5%
Cisplatin
5%
Lopinavir
5%
High-performance Liquid Chromatography
5%
Non-small Cell Lung Cancer (NSCLC)
5%
4-hydroxycyclophosphamide
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Therapeutic Drug Monitoring
22%
Pharmacodynamics
18%
Malignant Neoplasm
16%
Cyclophosphamide
16%
HIV
15%
Anticarcinogen
14%
Carboplatin
13%
Docetaxel
13%
Thiotepa
13%
Ritonavir
12%
Chemotherapy
12%
Paclitaxel
11%
Solid Malignant Neoplasm
11%
Neoplasm
9%
Nevirapine
9%
Non Small Cell Lung Cancer
9%
Breast Cancer
8%
Monoclonal Antibody
7%
Pazopanib
7%
Capecitabine
7%
Clinical Trial
6%
Active Metabolite
6%
High Dose Chemotherapy
6%
Sunitinib
6%
Efavirenz
6%
Cmin
6%
Indisulam
6%
High Performance Liquid Chromatography
6%
Elimination
5%
Neutropenia
5%
Gemcitabine
5%
Cisplatin
5%
Proteinase Inhibitor
5%
Drug-Drug Interaction
5%
Adverse Event
5%
Tamoxifen
5%
